Clinical Trial Update: Manipulating Ghrelin Signaling Via GOAT Inhibition in Alcohol Use Disorder [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating a GOAT inhibitor to manipulate ghrelin signaling for Alcohol Use Disorder; results have been posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder

Drugs mentioned

• GOAT inhibitor

Snippet

Sponsor: National Institute on Drug Abuse (NIDA) | Conditions: Alcohol Use Disorder | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-01-15